Literature DB >> 17554513

The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles.

B Hall1, M Andreeff, F Marini.   

Abstract

Recent evidence suggests that mesenchymal stem cells (MSC) selectively proliferate to tumors and contribute to the formation of tumor-associated stroma. The biological rationale for tumor recruitment of MSC remains unclear but may represent an effort of the host to blunt tumor cell growth and improve survival. There is mounting experimental evidence that normal stromal cells can revert malignant cell behavior, and separate studies have demonstrated that stromal cells can enhance tumor progression after acquisition of tumor-like genetic lesions. Together, these observations support the rationale for modifying normal MSC to deliver therapeutic proteins directly into the tumor microenvironment. Modified MSC can produce high concentrations of antitumor proteins directly within the Tumor mass, which have been shown to blunt tumor growth kinetics in experimental animal model systems. In this chapter we will address the biological properties of MSC within the tumor microenvironment and discuss the potential use of MSC and other bone marrow-derived cell populations as delivery vehicles for antitumor proteins.

Entities:  

Mesh:

Year:  2007        PMID: 17554513     DOI: 10.1007/978-3-540-68976-8_12

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  71 in total

1.  Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice.

Authors:  Chiyo Doi; Dharmendra Kumar Maurya; Marla M Pyle; Deryl Troyer; Masaaki Tamura
Journal:  Cytotherapy       Date:  2010-05       Impact factor: 5.414

Review 2.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Authors:  Diptiman Chanda; Sanjay Kumar; Selvarangan Ponnazhagan
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

3.  A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions.

Authors:  Hui-Yuan Hou; Hong-Liang Liang; Yu-Sheng Wang; Zhao-Xia Zhang; Bai-Ren Wang; Yuan-Yuan Shi; Xiao Dong; Yan Cai
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

4.  Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells.

Authors:  Eun Su Jeon; Soon Chul Heo; Il Hwan Lee; Yoon Ji Choi; Ji Hye Park; Kyung Un Choi; Do Youn Park; Dong Soo Suh; Man Soo Yoon; Jae Ho Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

5.  Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.

Authors:  J L Dembinski; E L Spaeth; J Fueyo; C Gomez-Manzano; M Studeny; M Andreeff; F C Marini
Journal:  Cancer Gene Ther       Date:  2009-10-30       Impact factor: 5.987

6.  CCL21 Chemokine Therapy for Lung Cancer.

Authors:  Sherven Sharma; Li Zhu; Minu K Srivastava; Marni Harris-White; Min Huang; Jay M Lee; Fran Rosen; Gina Lee; Gerald Wang; Valerie Kickhoefer; Leonard H Rome; Felicita Baratelli; Maie St John; Karen Reckamp; Seok Chul-Yang; Sven Hillinger; Robert Strieter; Steven Dubinett
Journal:  Int Trends Immun       Date:  2013-01

7.  Mesenchymal stem-like cells isolated from human esophageal carcinoma and adjacent non-cancerous tissues.

Authors:  Jiabo Hu; Zhongwei Zhou; Shunbin Shi; Xiaozhong Zhu; Xiaohui Wang; Wei Zhang; Sanqiang Hu; Hui Qian; Wenrong Xu
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

8.  Tumor cell behaviour modulation by mesenchymal stromal cells.

Authors:  Lucia Kucerova; Miroslava Matuskova; Kristina Hlubinova; Veronika Altanerova; Cestmir Altaner
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

9.  Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Authors:  Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow
Journal:  Mol Cancer       Date:  2010-11-18       Impact factor: 27.401

10.  Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma.

Authors:  Dharmendra K Maurya; Chiyo Doi; Atsushi Kawabata; Marla M Pyle; Clay King; Zhihong Wu; Deryl Troyer; Masaaki Tamura
Journal:  BMC Cancer       Date:  2010-10-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.